Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04659811 · ClinicalTrials.gov registry record · Phase 2

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

A Phase 2 study of Recurrent Meningioma and Grade I Meningioma, Adult, sponsored by Nancy Ann Oberheim Bush, MD.

Recruiting
Registry status
Phase 2
Development phase
37
Enrollment target
1
Study location

NCT04659811 is a Phase 2 study of Recurrent Meningioma and Grade I Meningioma, Adult that is actively recruiting participants, run by Nancy Ann Oberheim Bush, MD. The registered enrollment target is 37 participants, below the 47-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04659811, a Phase 2 study of Recurrent Meningioma and Grade I Meningioma, Adult, is actively recruiting participants, sponsored by Nancy Ann Oberheim Bush, MD.

RECRUITING
Registry status
Phase 2
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the effect of stereotactic radiosurgery and pembrolizumab in treating patients with meningioma that has come back (recurrent). Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. Pembrolizumab is a humanized monoclonal antibody. An antibody is a common type of protein made in the body in response to a foreign substance. Antibodies attack foreign substances and protect against infection. Antibodies can also be produced in the laboratory for use in treating patients; an antibody that is made in the lab is also known as a humanized monoclonal antibody. Pembrolizumab is a highly selective humanized monoclonal antibody that is designed to block the action of the receptor PD-1. It has been studied in lab experiments and in other types of cancer. The PD-1 receptor works to keep the immune system from noticing tumor cells. The addition of pembrolizumab to stereotactic radiosurgery may improve the progression free survival of patients with meningioma.

Conditions Studied

Recurrent Meningioma Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult

Interventions

  • DRUG Pembrolizumab
  • PROCEDURE Stereotactic Radiosurgery

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2021-03-25
Est. Completion 2030-04-30
Phase Phase 2

Sponsor

Nancy Ann Oberheim Bush, MD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04659811

The ClinicalTrials.gov registry entry for NCT04659811 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (21% lower). The listed sponsor is Nancy Ann Oberheim Bush, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Recurrent Meningioma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT04659811 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04659811 about?

NCT04659811 is a clinical study titled "Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma". This phase II trial studies the effect of stereotactic radiosurgery and pembrolizumab in treating patients with meningioma that has come back (recurrent). Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single...

What is the current status of trial NCT04659811?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2021-03-25. Estimated completion is 2030-04-30.

What conditions does trial NCT04659811 study?

This clinical trial studies the following conditions: Recurrent Meningioma, Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult.

What interventions are being tested in trial NCT04659811?

The interventions under investigation include: Pembrolizumab (DRUG), Stereotactic Radiosurgery (PROCEDURE).

Who is sponsoring clinical trial NCT04659811?

This trial is sponsored by Nancy Ann Oberheim Bush, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04659811 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Meningioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Meningioma

All registered trials for this condition

Grade I Meningioma, Adult

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.